Navigation Links
ERT Unveils Full Range of ePRO Solutions Providing the Power of Choice for Clinical Trial Sponsors
Date:12/16/2010

PHILADELPHIA, Dec. 16, 2010 /PRNewswire/ -- ERT (Nasdaq: ERES), a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries, today announced the launch of its comprehensive suite of electronic patient-reported outcome (ePRO) solutions. As the ePRO market continues to grow, ePRO tools have increasingly become more sophisticated, with their development reflecting the diverse needs of sponsors and facilitating compliance by the patient. ERT now offers a broad range of proven modalities of technology, offering the ability to choose the best ePRO solution to suit the requirements of the trial, ensuring its accuracy and success.

The selection of the ideal ePRO modality is reliant on multiple factors including questionnaire complexity, length, site location, patient population, budget and size of trial. To facilitate this complex selection criteria, ERT offers a diverse range of complementary ePRO tools accepted by regulatory authorities globally for collection of reliable accurate data. ERT solutions include the VIAPhone®, VIAPad®, VIAPen® and VIAWeb®, all of which offer the advantages of simplicity, mobility and immediacy of use over traditional paper based methods.  

ERT's VIAPad solution has the capacity for complex diaries, questionnaires and visual scales, alongside the ability to streamline mid-study changes. The VIAWeb solution enables all patients to use a standard internet browser at home or work to securely log into their study diary or assessment and complete necessary information. This is ideal for patients busy at work, with little time to visit a clinical trial site. The VIAPen is a digital pen that offers the simplicity of paper-based methods with the dual advantage of digital data collection. Completing the suite of solutions offered is the VIAPhone, otherwise known as an Interactive Voice Response device. The VIAPhone enables a patient to use a standard landline telephone or cell phone to feedback information. For people reluctant to embrace more innovative technologies or with reduced physical function, this provides the perfect solution.

John Blakeley, Executive Vice President and Chief Commercial Officer at ERT comments, "At ERT we believe that 'one size does NOT fit all.' We believe that to ensure an accurate and successful clinical trial, vendors must offer technologies that are as diverse and varied as the clinical trials themselves. With this in mind, ERT works to ensure that it offers a comprehensive, unbiased choice of sophisticated solutions."

For further information on ERT and its technology and services please email info@ert.com, call +1 215 972 0420 or visit www.ert.com.

For further press information, please contact Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, Email ert@scottpr.co.uk

About ERT

Based in Philadelphia, PA, eResearchTechnology, Inc. (www.ert.com) is a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries.  The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. It is also a leading provider of centralized respiratory technology and services to evaluate pulmonary function efficacy and safety in clinical development.  Sponsors can further use the Company's solutions to streamline the clinical trials process by automating the collection, analysis, and distribution of ePRO clinical data using multi-mode technology in all phases of clinical development as well as selected medical devices for the clinical trials and healthcare industries.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements.  These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE ERT
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CO-REC Unveils List of Approved Electronic Health Record Products
2. Siemens Unveils Biograph mMR Whole-Body Integrated MR-PET System Capable of Simultaneous Data Acquisition
3. Forte Research Systems Unveils the Allegro™ Research on Demand Cloud-Based Product Line
4. Panasonic Unveils CardioHealth® Station at American Heart Association 2010
5. Panasonic Unveils CardioHealth® Station - First Comprehensive Screening Solution to Detect Heart Disease in Asymptomatic Population
6. Biopharma Company UCB Unveils 40 Deserving 2010 Family Epilepsy Scholarship Recipients
7. Shrink Nanotechnologies Unveils Videos of StemDisc450 Prototype Growing Human Embryonic Stem Cells
8. Cleveland Clinic Unveils Top 10 Medical Innovations for 2011
9. Thomson Reuters Unveils Pharmacy Xpert Solution to Improve Medication Management for Hospital Pharmacists
10. Express Scripts Unveils New Opportunities to Drive Down Healthcare Costs; Presents Five Studies at Academy of Managed Care Pharmacy Conference
11. Inc. Magazine Unveils 29th Annual List of Americas Fastest-Growing Private Companies—the Inc. 500
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2017)... 2017 Therapix Biosciences Ltd. (Nasdaq: TRPX), ... the development of cannabinoid-based drugs, today announced that ... at three upcoming scientific and investor conferences in ... Invitational: ...                     Wednesday, June ...
(Date:5/26/2017)... , May 26, 2017  Endo International plc (NASDAQ: ... President and CEO, will represent the Company in a fireside ... Conference on Tuesday, June 13, 2017 at 10:40 a.m. PT ... Terranea Resort in Rancho Palos Verdes, CA. ... the event will be available on the Company,s website at ...
(Date:5/24/2017)... , May 24, 2017  ivWatch LLC ... Equipment Manufacturer (OEM) Board to enable seamless integration ... patient monitoring systems, infusion pumps and other devices. ... will be able to help health care customers ... reduced risks related to IV therapy. ...
Breaking Medicine Technology:
(Date:6/22/2017)... ... June 22, 2017 , ... United Benefit ... welcome Whipple & Company as its newest Partner Firm. Headquartered in Coconut Creek, ... clients’ risk while tailoring optimized benefit packages that strengthen the relationship between employer ...
(Date:6/22/2017)... ... June 22, 2017 , ... Children’s National ... Heart Association (AHA) to launch a Rheumatic Heart Disease Center, with the goal ... of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries and low-income communities ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... environmental excellence. Maryland Recycling Network has awarded the Baltimore VA Medical Center, a ... Government Program Award for its efforts to promote waste reduction and promote recycling. ...
(Date:6/22/2017)... ... ... A June 12 article in The Star offers the advice ... oral hygiene by an aged parent who had recently suffered a series of minor ... steps, including scheduling a dentist visit. Northridge Dental Works, a Los Angeles Area dental ...
(Date:6/20/2017)... Murfreesboro, Tennessee (PRWEB) , ... June 20, 2017 ... ... chronic care services, announced today that Claritas Capital, a Nashville-based private equity firm, ... to accelerate our expansion plans for some time, and Claritas Capital offers the ...
Breaking Medicine News(10 mins):